Investigational daily pill doubles survival in metastatic pancreatic cancer, study shows
Likely Human
Key takeaways A study co-led by UCLA found patients who received daraxonrasib, an investigational, first-in-class oral drug designed to block one of the primary drivers of pancreatic cancer, lived a median...
The Verdict
ClassificationLikely Human
ConfidenceMedium confidence
Analyzedtext
Community Verdict
Sign in to vote
Be the first to vote on this assessment.
Embed Badge
Add this badge to your site to show the AI classification for this content.
[](https://real.press/content/0b1aa609-f633-4769-bc16-986bba607c67)